9h
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value CreationCompletion of Tedopi’s phase 3 in Non-Small ...
One unverifiable ingredient. A voluntary shutdown. An IRS audit. How telling the truth took Branch Basics from failure to $50 million.
Viking Therapeutics advances oral and injectable VK2735 for obesity with strong cash, pipeline depth, and key 2026 catalysts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback